Christoph Sarrazin

Hepatology · 2007–2018

A researcher in the Science corpus: 8 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Christoph Sarrazin trusts

Their strongest outbound trust, strongest first, inferred from their citations.

  1. D. Lavanchy (in Hepatology)

Papers from Christoph Sarrazin's perspective

Ordered by how strongly the researchers Christoph Sarrazin trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. (New England Journal of Medicine)
  2. Telaprevir for retreatment of HCV infection. (New England Journal of Medicine)
  3. Sofosbuvir for previously untreated chronic hepatitis C infection. (New England Journal of Medicine)
  4. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. (New England Journal of Medicine)
  5. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. (New England Journal of Medicine)
  6. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive… (The Lancet)
  7. Sampling variability of liver fibrosis in chronic hepatitis C (Hepatology)
  8. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. (Ultrasound in Medicine and Biology)
  9. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. (New England Journal of Medicine)
  10. Prospective Comparison of Transient Elastography, Fibrotest, APRI, and Liver Biopsy for the Assessment of Fibrosis in Chronic Hepatitis CCastéra L, Vergniol J, Foucher J, et al (Hôpital Haut…

Their papers